News Medical11h
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Managed Healthcare Executive1d
Blood or Marrow Transplant Recipients Face Higher Skin Cancer Risk, Study Shows
Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...
PharmaTimes3d
Libtayo available in Scotland for cervical cancer patients
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
PharmiWeb4d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...